Trademark Opposition Extension - O Mark

The USPTO Trademark Trial and Appeal Board received a 60-day extension request from The Ohio State University to oppose Onus Health LLC's trademark application for the mark 'O'. The original opposition deadline was set for December 2025. TTAB case number 99218186.

Patek Philippe Requests 90-Day Extension to Oppose THE TWENTYFOUR SIX Mark

The USPTO Trademark Trial and Appeal Board granted Patek Philippe SA Geneve's first 90-day request to extend the time to oppose trademark application THE TWENTYFOUR SIX. The extension was granted on April 5, 2026, for TTAB case TTAB79416218, originally filed December 4, 2025. This is a routine procedural extension in a trademark opposition proceeding.

Mediation Program Surpasses $6M in Settlements

The Oregon Bureau of Labor and Industries (BOLI) announced that its Mediation Program has surpassed $6 million in settlements between Oregon workers and employers. The milestone comes as the expanded mediation model continues to move forward, providing an alternative dispute resolution pathway for employment-related conflicts in the state.

Proposed Removal of Prescriptive Rule on Indirect Vehicle Loan Servicing

The NCUA Board published a proposed rule to remove prescriptive regulatory requirements governing third-party servicing of indirect vehicle loans currently codified at §§ 701.21(h) and 741.203(c). The existing rule limits indirect loans and participations purchased from any one servicer to 50% of a credit union's net worth (increasing to 100% after 30 months of experience). The proposal seeks comment on reducing regulatory burden and providing credit unions greater operational flexibility through a principles-based supervisory approach.

Generic Omeprazole Oral Paste Approved for Horse Gastric Ulcers

The FDA approved Gastrobim (omeprazole) oral paste as a generic equivalent to Gastrogard for the treatment and prevention of gastric ulcers in horses and foals four weeks of age and older. Sponsored by Bimeda Animal Health Ltd. of Ireland, the drug was determined bioequivalent to the brand-name product approved in 1999. Gastrobim is available only by prescription from a licensed veterinarian.

PROSECCO Trial: Cemiplimab Combination for Melanoma

ClinicalTrials.gov registered a new Phase III trial (NCT07511036) called PROSECCO, studying cemiplimab in combination therapy for melanoma. The trial is sponsored by Regeneron Pharmaceuticals and is currently listed as not recruiting. Cemiplimab is a PD-1 inhibitor marketed as Libtayo.

Clinical trial page for NCT07511049

Clinical trial page for NCT07511049

MEND II mindfulness neurostimulation for depression, UC San Diego

The National Library of Medicine registered a new clinical trial, NCT07512284, on ClinicalTrials.gov. The MEND II study will investigate mindfulness neurostimulation as an intervention for depression at UC San Diego.

Precision radiotherapy, molecular MRI, brain cancer, Johns Hopkins

The National Library of Medicine registered clinical trial NCT07512154 on ClinicalTrials.gov. The trial, sponsored by Johns Hopkins University, studies precision radiotherapy combined with molecular MRI for brain cancer. This registration fulfills requirements under 42 U.S.C. §282 for federally funded clinical trials to be publicly registered.

AML clinical trial investigating TP53 mutation treatment

The National Library of Medicine registered a new clinical trial on ClinicalTrials.gov (NCT07511062) investigating treatment for TP53 mutations in Acute Myeloid Leukemia (AML) patients. This is an informational registry entry providing public access to trial information as required under federal clinical trial registration requirements.